Topics

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq 

14:15 EDT 3 Oct 2019 | Pharmafile

Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq 

Original Article: Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq 

NEXT ARTICLE

More From BioPortfolio on "Novartis plans FDA approval as it hits endpoint for Consentyx in axial spondyloarthritis http://bit.ly/2oKRMSq "

Quick Search

Relevant Topic

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...